Cargando…

SAT461 Hearing-related Issues Associated With Graves’ Disease, Thyroid Eye Disease And Treatment With Teprotumumab

Disclosure: T.J. Smith: Consulting Fee; Self; Horizon Therapeutics plc, Viridian, Lundbeck. Other; Self; US patents covering the use of IGF-1 receptor inhibitors in TED which are held by UCLA and the Lundquist Institute. A. Qashqai: Employee; Self; Horizon Therapeutics plc. Stock Owner; Self; Horizo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, Terry J, Qashqai, Anahita, Barretto, Naina, Holt, Robert J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Thyroid
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553650/ http://dx.doi.org/10.1210/jendso/bvad114.1935

Ejemplares similares

PSAT261 Use of Steroids Pre- and Post-Teprotumumab in Thyroid Eye Disease Patients
por: Holt, Robert J, et al.
Publicado: (2022)

SAT-554 Teprotumumab in Graves' Orbitopathy: Extended Outcome Analyses
por: Kahaly, George, et al.
Publicado: (2019)

SAT471 Hearing-Related Adverse Events in Teprotumumab Oncology Clinical Trials
por: Smith, Terry J, et al.
Publicado: (2023)

OR11-4 Teprotumumab Markedly Improves Disease-related Quality of Life: Lessons From Two Randomized, Placebo-controlled Trials
por: Douglas, Raymond S, et al.
Publicado: (2022)

RF35 | PSAT263 Efficacy of Teprotumumab for Thyroid Eye Disease in Hypothyroid Patients
por: Smith, Terry J, et al.
Publicado: (2022)

FRI572 Teprotumumab In Unexplored Presentation Of Thyroid Eye Disease
por: Torres Torres, Marina T, et al.
Publicado: (2023)

SAT-461 NIFTP: A Painstaking Diagnosis Through the Pathologist’s Eyes
por: Chittimoju, Sanjita B, et al.
Publicado: (2020)

Hearing Loss and Teprotumumab
por: Kossler, Andrea, et al.
Publicado: (2021)

PSAT265 Blood Glucose in Thyroid Eye Disease (TED) in Patients treated with Teprotumumab: Clinical Trials Data
por: Smith, Terry J, et al.
Publicado: (2022)

SAT466 Inactive Thyroid Eye Disease Patient Journey
por: Cockerham, Kimberly, et al.
Publicado: (2023)

SAT-432 Pharmacokinetics (PK) and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor (IGF-1R) Blocking Antibody, in Active Thyroid Eye Disease (TED)
por: Xin, Yan, et al.
Publicado: (2020)

LBSAT238 Teprotumumab Reduces Orbital Fat And Muscle Volume In Patients With Thyroid Eye Disease
por: Ugradar, Shoaib
Publicado: (2022)

SAT455 A Randomized, Quadruple-masked, Placebo-controlled, Multicenter Trial To Evaluate The Efficacy And Safety Of Teprotumumab In Patients With Chronic (Inactive/Low CAS) Thyroid Eye Disease
por: Douglas, Raymond S, et al.
Publicado: (2023)

SAT-588 Unique Presentation of Postpartum Thyroiditis with Features of Graves' Disease
por: Havranova, Jana, et al.
Publicado: (2019)

SAT-581 Graves' Disease and Hashimoto's Thyroiditis: Two Ends of a Spectrum
por: Morselli, Lisa, et al.
Publicado: (2019)

SAT-415 Clinical Performance of Thyroid-Stimulating Immunoglobulin for Graves′ Disease Diagnosis
por: Marui, Suemi, et al.
Publicado: (2020)

SAT-497 Conversion of Hashimoto’s Thyroiditis to Grave’s Disease: A Case Report
por: Wahedi, Tayba S, et al.
Publicado: (2020)

SAT-423 Anti-thyroid Drug Response in Graves’ Disease: Predictors of Biochemically Persistent Disease
por: El Kawkgi, Omar M, et al.
Publicado: (2020)

SAT-476 Alemtuzumab Induced Graves Disease
por: Caputi, Rafael C, et al.
Publicado: (2020)

SAT489 Grave’s Disease Secondary To Alemtuzumabuse
por: Gong, Michael Shifeng, et al.
Publicado: (2023)

RF35 | PSAT268 Reversal of Graves’ Disease Associated Facial Volume Expansion and Eyelid Changes Following Teprotumumab Therapy
por: Ugradar, Shoaib, et al.
Publicado: (2022)

SAT459 Teprotumumab Pooled Efficacy From The European Study Sites Participating In The Phase 2, OPTIC (Phase 3) And OPTIC-X Pivotal Trials
por: Kahaly, George J, et al.
Publicado: (2023)

SAT-518 Progression of Graves Disease to Hashimoto’s Thyroiditis Following Alemtuzumab Therapy for Multiple Sclerosis
por: Rapier, Brandon, et al.
Publicado: (2020)

SAT553 A Case of Metastatic Functional Papillary Thyroid Cancer in the Setting of Graves’ Disease
por: Manuel, Nicholas, et al.
Publicado: (2023)

Rapidly Progressive Cognitive Decline and Varicella Zoster Blisters Associated With Teprotumumab in 2 Patients With Graves’ Orbitopathy
por: Hoang, Thanh Duc, et al.
Publicado: (2021)

OR18-01 Effect of Teprotumumab on Proptosis Reduction Across Various Demographic Sub-Groups
por: Kahaly, George J, et al.
Publicado: (2020)

SAT-603 Graves' Disease and an Anterior Mediastinal Mass
por: Robbins, D'lorah, et al.
Publicado: (2019)

SAT-592 Amiodarone-Induced Cure Of Graves' Disease
por: Sharma, Eliza, et al.
Publicado: (2019)

SAT-605 Immune Thrombocytopenic Purpura in Graves' disease
por: Sajja, Puspalatha, et al.
Publicado: (2019)

SAT-582 Autoimmune Hepatitis Presenting with Graves Disease
por: Coy, Andres, et al.
Publicado: (2019)

FRI554 Pretibial Myxedema Associated With Hashimoto Thyroiditis Treated With Teprotumumab
por: Marta Niedzialkowska, Ewelina, et al.
Publicado: (2023)

MON-461 A Rare Case of Thyroglobulin Deficiency with Ectopic Thyroid Tissue
por: Venkataraman, Sandhya, et al.
Publicado: (2020)

PSAT355 A Case Report Identifying Graves’ Ophthalmopathy in a Myasthenia Gravis Crisis and Response to Teprotumumab
por: Zia, Abdul, et al.
Publicado: (2022)

SAT-422 Evaluation of the Siemens Thyroid Stimulating Immunoglobulin (TSI) Assay for Diagnosis and Prognosis of Graves’ Disease
por: Paul, Heather, et al.
Publicado: (2020)

SAT548 Incidental Papillary Thyroid Carcinoma Diagnosed After Total Thyroidectomy For Recurrent Grave's Disease
por: Perez-Martinez, Sebastian U, et al.
Publicado: (2023)

SAT-500 Response to Tocilizumab Retreatment in Refractory Thyroid Eye Disease
por: Kaplan, Daniel, et al.
Publicado: (2020)

SAT-428 Sex-Specific Risk Gene of Graves’ Disease
por: Zhao, Shuangxia, et al.
Publicado: (2020)

SAT462 TSI Versus TRAb In The Diagnosis Of Grave’s Disease
por: Ibrahim, Katherine, et al.
Publicado: (2023)

OR27-04 Efficacy And Safety Results From The Randomized, Placebo-controlled Multicenter Trial With Teprotumumab In Chronic-Low Clinical Activity Score Thyroid Eye Disease Patients
por: Douglas, Raymond S, et al.
Publicado: (2023)

SAT490 Graves’ Disease In Remission Aggravated By Himalayan Salt Consumption
por: Shakir, Mohamed K M, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k0cqs3biuvjudbf15voaubhgt3